Weight-loss drugs dim food reward via amygdala in mice

GLP-1 receptor agonists reliably reduce body weight and improve metabolic outcomes, but the established peptide drugs must be injected and are complex to manufacture. Small-molecule versions promise oral dosing and scalable production, yet they bind human receptors far more selectively than rodent ones, which has largely blocked the animal work needed to understand how they act on the brain. There is also a longstanding question about whether these drugs simply reduce hunger or separately dampen the pleasure-driven pull of highly palatable food. This study was designed to answer that with tools that let human-targeted compounds work in a mouse.

The researchers built humanised GLP1R mouse models so that small-molecule GLP-1 receptor agonists would engage the receptor in living animals, then traced which neuron populations the compounds recruited during feeding. Alongside the canonical hypothalamic and hindbrain networks that govern metabolic homeostasis, they focused on a discrete population of Glp1r-expressing neurons in the central amygdala. They measured dopamine release in the nucleus accumbens, directly stimulated the central amygdalar neurons to see what happened to feeding, and used targeted deletion of the receptor in that specific cell population to test whether it was required for the drug's effect.

The compounds regulated both homeostatic and hedonic feeding, but through parallel neural circuits rather than a single pathway. The central amygdala Glp1r neurons selectively suppressed consumption of palatable foods, and did so by reducing dopamine release in the nucleus accumbens. Artificially stimulating those neurons was enough to curtail hedonic feeding on its own. Conversely, deleting the receptor from that cell population specifically diminished the drugs' anorectic efficacy for reward-driven intake, implying the population is necessary for the palatable-food effect while the homeostatic arm is handled elsewhere. The authors frame the circuit as relevant to binge eating and substance-use disorder as well as obesity.

Clinical reports of reduced craving on GLP-1 drugs have long hinted that reward processing is involved, but the receptor-level anatomy in a living animal has been hard to pin down precisely because small molecules are human-selective. By humanising the receptor, this work supplies a candidate circuit and a plausible mechanism: less dopamine release in the nucleus accumbens when palatable food is on offer. It complicates the simple 'these drugs just make you full' account. Open questions include whether the same circuit operates in humans, whether it explains reported effects on alcohol or other rewards, and how it behaves over long-term dosing.

For a reader following the GLP-1 story, this is a reason to think the appetite effects of these drugs are not one thing: homeostatic hunger and the pull of tasty food appear to be handled by separate circuits that the same drug can hit. That helps explain why people describe food becoming less interesting rather than simply feeling stuffed. It is animal work in genetically modified mice, so it says nothing about dosing, efficacy or safety in humans. Its main value is as a map of mechanism, and as an early hint that the same circuit could matter for binge eating.